Close Menu

NEW YORK – The US Food and Drug Administration has granted accelerated approval to entrectinib (Genentech's Rozlytrek) as a treatment for adult and adolescent patients whose cancers have NTRK gene fusions and are out of treatment options.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.